NASDAQ:GLPG - GALAPAGOS NV/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$104.12 -3.38 (-3.14 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$107.50
Today's Range$103.89 - $106.36
52-Week Range$87.36 - $122.28
Volume106,600 shs
Average Volume80,558 shs
Market Capitalization$5.51 billion
P/E Ratio-39.44
Dividend YieldN/A
Beta1.89
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; and AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLPG
Previous Symbol
CUSIPN/A
Phone321-534-2900

Debt

Debt-to-Equity RatioN/A
Current Ratio5.17
Quick Ratio5.17

Price-To-Earnings

Trailing P/E Ratio-39.44
Forward P/E Ratio-60.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$176.13 million
Price / Sales30.29
Cash FlowN/A
Price / Cash FlowN/A
Book Value$22.46 per share
Price / Book4.64

Profitability

EPS (Most Recent Fiscal Year)($2.64)
Net Income$-130,780,000.00
Net Margins-30.65%
Return on Equity-7.66%
Return on Assets-5.85%

Miscellaneous

Employees600
Outstanding Shares51,240,000
Market Cap$5.51 billion
OptionableOptionable

GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions

What is GALAPAGOS NV/S's stock symbol?

GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."

How were GALAPAGOS NV/S's earnings last quarter?

GALAPAGOS NV/S (NASDAQ:GLPG) posted its quarterly earnings data on Friday, October, 26th. The biotechnology company reported $0.33 earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.70. The biotechnology company earned $119.99 million during the quarter, compared to analysts' expectations of $82.15 million. GALAPAGOS NV/S had a negative return on equity of 7.66% and a negative net margin of 30.65%. View GALAPAGOS NV/S's Earnings History.

When is GALAPAGOS NV/S's next earnings date?

GALAPAGOS NV/S is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for GALAPAGOS NV/S.

What price target have analysts set for GLPG?

10 brokers have issued 12-month target prices for GALAPAGOS NV/S's shares. Their predictions range from $90.00 to $157.00. On average, they anticipate GALAPAGOS NV/S's share price to reach $122.6250 in the next year. This suggests a possible upside of 17.8% from the stock's current price. View Analyst Price Targets for GALAPAGOS NV/S.

What is the consensus analysts' recommendation for GALAPAGOS NV/S?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GALAPAGOS NV/S.

Has GALAPAGOS NV/S been receiving favorable news coverage?

Media headlines about GLPG stock have trended very negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. GALAPAGOS NV/S earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of GALAPAGOS NV/S's key competitors?

Who are GALAPAGOS NV/S's key executives?

GALAPAGOS NV/S's management team includes the folowing people:
  • Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 59)
  • Mr. Bart Filius MBA, CFO & COO (Age 48)
  • Dr. Piet Wigerinck, Chief Scientific Officer (Age 54)
  • Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. Communications
  • Dr. Andre Hoekema, Chief Bus. Officer (Age 61)

When did GALAPAGOS NV/S IPO?

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

Who are GALAPAGOS NV/S's major shareholders?

GALAPAGOS NV/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Federated Investors Inc. PA (3.27%), FMR LLC (1.43%), BlackRock Inc. (0.71%), Baker BROS. Advisors LP (0.46%), Credit Suisse AG (0.37%) and Jane Street Group LLC (0.36%).

Which institutional investors are selling GALAPAGOS NV/S stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Aquilo Capital Management LLC, Dorsey Wright & Associates, Alliancebernstein L.P., Baker BROS. Advisors LP, Peregrine Capital Management LLC and Macquarie Group Ltd..

Which institutional investors are buying GALAPAGOS NV/S stock?

GLPG stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Laurion Capital Management LP, Marshall Wace LLP, Jane Street Group LLC, Credit Suisse AG, Monashee Investment Management LLC, BlackRock Inc. and Janus Henderson Group PLC.

How do I buy shares of GALAPAGOS NV/S?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GALAPAGOS NV/S's stock price today?

One share of GLPG stock can currently be purchased for approximately $104.12.

How big of a company is GALAPAGOS NV/S?

GALAPAGOS NV/S has a market capitalization of $5.51 billion and generates $176.13 million in revenue each year. The biotechnology company earns $-130,780,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. GALAPAGOS NV/S employs 600 workers across the globe.

What is GALAPAGOS NV/S's official website?

The official website for GALAPAGOS NV/S is http://www.glpg.com.

How can I contact GALAPAGOS NV/S?

GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]


MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  571
MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel